{"name":"Renovaro","slug":"renovaro","ticker":"RENB","exchange":"NASDAQ","domain":"renovarobio.com","description":"Renovaro is a biotechnology company focused on developing innovative cell and gene therapies, as well as AI-powered diagnostic solutions. The company's pipeline includes several promising candidates in various stages of development. Renovaro has established itself as a key player in the rapidly growing cell and gene therapy market, with a strong presence in the US and globally.","hq":"Los Angeles, CA","founded":2015,"employees":"~75,000","ceo":"Mark Bhatt","sector":"Cell & Gene Therapy / AI Diagnostics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153.4B","metrics":{"revenue":2500000,"revenueGrowth":0,"grossMargin":0,"rdSpend":537428,"netIncome":-178007489,"cash":8230840,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"REN-001 patent cliff ($500M at risk)","drug":"REN-001","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"REN-002 patent cliff ($200M at risk)","drug":"REN-002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Renovaro Receives FDA Approval for Gene Therapy Candidate REN-001","summary":"Renovaro announced that the FDA has approved its gene therapy candidate REN-001 for the treatment of a rare genetic disorder.","drugName":"REN-001","sentiment":"positive"},{"date":"2023-11-10","type":"earnings","headline":"Renovaro Reports Strong Q3 Earnings, Beats Expectations","summary":"Renovaro reported strong Q3 earnings, beating analyst expectations and driven by the success of its cell and gene therapy products.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Renovaro Partners with AI Firm to Develop AI-Powered Diagnostic Solutions","summary":"Renovaro announced a partnership with a leading AI firm to develop AI-powered diagnostic solutions for various diseases.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5pZVF6LUNZemhteVE1UUtCNHY3akRtWWRhS19CazlkclZRVmV5ekR1WTZoZzFfblpCb1pDaXhEYVEzMVdvQUFob2NwUm5ZOENHbkFwejlodnpPbnNyYThlNU1SalpqeGxBS1d1S3ZB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Renovaro (RENB) - Stock Titan","headline":"If You Invested $1,000 in Renovaro (RENB)","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-09-29","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaEl4OTNJYUowbzVzdzhYYkc3SldBMUNZVXJfY2YtZ29xakZFakV5czNBXzRYVXY0WkN6cnkwd3FDWmY3bXFiTF9BWGhRTjdsYVdwcFBZbW12RnI2Y2dGalVpTW92WDRFeU43YU53YWlxZjNYMTJEay1yTVdCMjlIQzZoRExsVE9oeHgwRVQ2dHBJbVVYX0VMOUFQT19lZzBTSl95LUY5a2hQSUN6bjd2RkZ3R0JYYzJEc0RKVWJMN2M?oc=5","date":"2025-09-09","type":"pipeline","source":"Stock Titan","summary":"First-Ever AI Safety Platform: Lunai Bioworks Launches Transformer Tech to Secure Drug Discovery & Block Biothreat - Stock Titan","headline":"First-Ever AI Safety Platform: Lunai Bioworks Launches Transformer Tech to Secure Drug Discovery & Block Biothreat","sentiment":"neutral"}],"patents":[{"drugName":"REN-002","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":200000000},{"drugName":"REN-001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioMarin","Spark Therapeutics","Editas Medicine"],"therapeuticFocus":["Rare Genetic Disorders","Cancer"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2012-03-31","revenueHistory":[{"value":0,"period":"2012-03-31"},{"value":0,"period":"2012-03-31"},{"value":0,"period":"2011-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":537428,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-178007489,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8230840,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}